Enovis Corp (ENOV) - Net Assets
Based on the latest financial reports, Enovis Corp (ENOV) has net assets worth $1.49 Billion USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.83 Billion) and total liabilities ($2.34 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ENOV asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.49 Billion |
| % of Total Assets | 38.9% |
| Annual Growth Rate | 13.84% |
| 5-Year Change | -67.99% |
| 10-Year Change | -51.77% |
| Growth Volatility | 282.11 |
Enovis Corp - Net Assets Trend (2004–2025)
This chart illustrates how Enovis Corp's net assets have evolved over time, based on quarterly financial data. Also explore ENOV total assets for the complete picture of this company's asset base.
Annual Net Assets for Enovis Corp (2004–2025)
The table below shows the annual net assets of Enovis Corp from 2004 to 2025. For live valuation and market cap data, see market cap of Enovis Corp.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.49 Billion | -41.82% |
| 2024-12-31 | $2.56 Billion | -25.03% |
| 2023-12-31 | $3.42 Billion | -0.84% |
| 2022-12-31 | $3.45 Billion | -25.99% |
| 2021-12-31 | $4.66 Billion | +29.92% |
| 2020-12-31 | $3.59 Billion | +2.82% |
| 2019-12-31 | $3.49 Billion | +0.36% |
| 2018-12-31 | $3.48 Billion | -6.72% |
| 2017-12-31 | $3.73 Billion | +20.49% |
| 2016-12-31 | $3.09 Billion | -5.01% |
| 2015-12-31 | $3.26 Billion | -2.86% |
| 2014-12-31 | $3.35 Billion | +22.30% |
| 2013-12-31 | $2.74 Billion | +27.12% |
| 2012-12-31 | $2.16 Billion | +1039.23% |
| 2011-12-31 | $189.28 Million | -12.52% |
| 2010-12-31 | $216.37 Million | +8.82% |
| 2009-12-31 | $198.83 Million | +19.11% |
| 2008-12-31 | $166.93 Million | +214.66% |
| 2007-12-31 | $53.05 Million | +799.32% |
| 2006-12-31 | $5.90 Million | +177.83% |
| 2005-12-31 | $-7.58 Million | -107.73% |
| 2004-12-31 | $98.09 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Enovis Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 146746300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $57.00K | 0.00% |
| Other Comprehensive Income | $-91.36 Million | -6.13% |
| Other Components | $3.05 Billion | 204.64% |
| Total Equity | $1.49 Billion | 100.00% |
Enovis Corp Competitors by Market Cap
The table below lists competitors of Enovis Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Japfa Comfeed Indonesia Tbk
JK:JPFA
|
$1.34 Billion |
|
Aurisco Pharmaceutical Co Ltd
SHG:605116
|
$1.34 Billion |
|
Nomad Foods Ltd
NYSE:NOMD
|
$1.34 Billion |
|
Haima Automobile Group Co Ltd
SHE:000572
|
$1.35 Billion |
|
Sichuan Jinlu Group Co Ltd
SHE:000510
|
$1.34 Billion |
|
VGI Public Company Limited
BK:VGI-R
|
$1.34 Billion |
|
Thangamayil Jewellery Limited
NSE:THANGAMAYL
|
$1.34 Billion |
|
Inox Wind Energy Limited
NSE:IWEL
|
$1.34 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Enovis Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,562,262,000 to 1,489,645,000, a change of -1,072,617,000 (-41.9%).
- Net loss of 1,184,440,000 reduced equity.
- New share issuances of 1,318,000 increased equity.
- Other comprehensive income increased equity by 36,529,000.
- Other factors increased equity by 73,976,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.18 Billion | -79.51% |
| Share Issuances | $1.32 Million | +0.09% |
| Other Comprehensive Income | $36.53 Million | +2.45% |
| Other Changes | $73.98 Million | +4.97% |
| Total Change | $- | -41.86% |
Book Value vs Market Value Analysis
This analysis compares Enovis Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.89x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.74x to 0.89x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $13.45 | $23.34 | x |
| 2005-12-31 | $-1.04 | $23.34 | x |
| 2006-12-31 | $0.81 | $23.34 | x |
| 2007-12-31 | $7.27 | $23.34 | x |
| 2008-12-31 | $14.90 | $23.34 | x |
| 2009-12-31 | $13.73 | $23.34 | x |
| 2010-12-31 | $14.81 | $23.34 | x |
| 2011-12-31 | $12.83 | $23.34 | x |
| 2012-12-31 | $63.32 | $23.34 | x |
| 2013-12-31 | $74.35 | $23.34 | x |
| 2014-12-31 | $76.11 | $23.34 | x |
| 2015-12-31 | $73.76 | $23.34 | x |
| 2016-12-31 | $70.54 | $23.34 | x |
| 2017-12-31 | $84.69 | $23.34 | x |
| 2018-12-31 | $81.16 | $23.34 | x |
| 2019-12-31 | $75.54 | $23.34 | x |
| 2020-12-31 | $76.53 | $23.34 | x |
| 2021-12-31 | $90.29 | $23.34 | x |
| 2022-12-31 | $63.78 | $23.34 | x |
| 2023-12-31 | $62.73 | $23.34 | x |
| 2024-12-31 | $46.35 | $23.34 | x |
| 2025-12-31 | $26.23 | $23.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Enovis Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -79.51%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -52.69%
- • Asset Turnover: 0.59x
- • Equity Multiplier: 2.57x
- Recent ROE (-79.51%) is below the historical average (5.08%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 58.42% | 18.51% | 0.44x | 7.22x | $47.50 Million |
| 2005 | 0.00% | 3.54% | 0.49x | 0.00x | $13.00 Million |
| 2006 | 1.59% | 0.02% | 0.49x | 135.15x | $-495.90K |
| 2007 | 122.30% | 12.81% | 0.56x | 16.90x | $59.58 Million |
| 2008 | -0.34% | -0.09% | 0.66x | 5.47x | $-17.26 Million |
| 2009 | 10.92% | 4.14% | 0.52x | 5.05x | $1.84 Million |
| 2010 | 7.49% | 2.99% | 0.53x | 4.72x | $-5.42 Million |
| 2011 | 2.41% | 0.66% | 0.64x | 5.75x | $-14.37 Million |
| 2012 | -3.37% | -1.65% | 0.64x | 3.21x | $-255.64 Million |
| 2013 | 7.11% | 4.25% | 0.64x | 2.62x | $-72.76 Million |
| 2014 | 12.46% | 8.48% | 0.64x | 2.30x | $77.42 Million |
| 2015 | 5.46% | 4.23% | 0.59x | 2.19x | $-139.26 Million |
| 2016 | 4.42% | 3.51% | 0.57x | 2.20x | $-161.58 Million |
| 2017 | 4.32% | 4.58% | 0.49x | 1.92x | $-198.95 Million |
| 2018 | 4.29% | 6.39% | 0.33x | 2.02x | $-186.78 Million |
| 2019 | -15.33% | -15.86% | 0.45x | 2.15x | $-871.79 Million |
| 2020 | 1.20% | 1.39% | 0.42x | 2.07x | $-311.71 Million |
| 2021 | 1.55% | 5.02% | 0.17x | 1.84x | $-390.08 Million |
| 2022 | -0.39% | -0.85% | 0.37x | 1.24x | $-358.10 Million |
| 2023 | -0.97% | -1.95% | 0.38x | 1.32x | $-375.10 Million |
| 2024 | -32.22% | -39.17% | 0.45x | 1.84x | $-1.08 Billion |
| 2025 | -79.51% | -52.69% | 0.59x | 2.57x | $-1.33 Billion |
Industry Comparison
This section compares Enovis Corp's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $290,647,834
- Average return on equity (ROE) among peers: -53.87%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Enovis Corp (ENOV) | $1.49 Billion | 58.42% | 1.57x | $1.34 Billion |
| Abbott Laboratories (ABT) | $2.73 Billion | 31.54% | 0.78x | $152.22 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-95.88 Million | 0.00% | 0.00x | $19.93 Million |
| Aethlon Medical Inc (AEMD) | $2.30 Million | -269.46% | 0.79x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $-225.81 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $280.85 Million | -57.55% | 5.46x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $9.37 Million | 23.33% | 0.30x | $15.73 Million |
| Allurion Technologies, Inc. (ALUR) | $-34.28 Million | 0.00% | 0.00x | $9.09 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $7.63 Million | -202.23% | 0.23x | $4.25 Million |
| Artivion Inc (AORT) | $208.98 Million | 5.16% | 0.51x | $1.70 Billion |
| Apyx Medical Inc (APYX) | $26.92 Million | -69.51% | 1.94x | $116.93 Million |
About Enovis Corp
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compres… Read more